260046-05-7

Basic information

• Product Name: N⁴-(2-chlorophenyl)-2-chloropyrimidine-4-amine
• Synonyms: N⁴-(2-chlorophenyl)-2-chloropyrimidine-4-amine
• CAS NO: 260046-05-7
• Molecular Weight: 240.092
• Mol File: 260046-05-7.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: N⁴-(2-chlorophenyl)-2-chloropyrimidine-4-amine(CAS DataBase Reference)
• NIST Chemistry Reference: N⁴-(2-chlorophenyl)-2-chloropyrimidine-4-amine(260046-05-7)
• EPA Substance Registry System: N⁴-(2-chlorophenyl)-2-chloropyrimidine-4-amine(260046-05-7)

Safety Data

• Hazardous Substances Data: 260046-05-7(Hazardous Substances Data)

Upstream product

• 3934-20-1 2,6-Dichloropyrimidine 
• 118-92-3 anthranilic acid 
• 95-51-2 o-chloroaniline 

Downstream Products

• 1395886-26-6 N₄-(2-chlorophenyl)-N₂-[4-(2H-tetrazol-5-yl)phenyl]pyrimidine-2,4-diamine hydrochloride 
• 1395885-94-5 N₄-(2-chlorophenyl)-N₂-[4-(methylsulfonyl)phenyl]pyrimidine-2,4-diamine 
• 1395886-03-9 N₄-(2'-chlorophenyl)-N₂-(4'-carboxy-3'-methoxyphenyl)pyrimidine-2,4-diamine hydrochloride 
• 1395887-04-3 N⁴-(2-chlorophenyl)-N⁴-ethyl-2-chloropyrimidine-4-amine 
• 1395887-00-9 N⁴-(2-chlorophenyl)-N⁴-methyl-2-chloropyrimidine-4-amine 
• 1395885-91-2 N₄-(2-chlorophenyl)-N₂-[4-N-(2-methoxyethyl)carbamoylphenyl]pyrimidine-2,4-diamine hydrochloride 
• 1395886-17-5 N₄-(2-chlorophenyl)-N₂-[4-N-(2-hydroxyethyl)carbamoylphenyl]pyrimidine-2,4-diamine 
• 1395886-00-6 5-((4-((2-chlorophenyl)amino)pyrimidin-2-yl)amino)-1H-benzo[d]imidazol-2(3H)-one hydrochloride 
• 1395885-97-8 N₄-(2-chlorophenyl)-N₂-(3-acetamidophenyl)pyrimidine-2,4-diamine hydrochloride 
• 1395885-82-1 methyl 4-(4-(2-chlorophenylamino)pyrimidin-2-ylamino)-2-hydroxybenzoate 
• 1395885-65-0 N₄-(2'-chlorophenyl)-N₂-(3'-carboxyphenyl)pyrimidine-2,4-diamine hydrochloride 
• 1395885-67-2 C₁₇H₁₄ClN₅O*ClH 
• 1395886-09-5 C₁₆H₁₄ClN₅O₂S*ClH 
• 1395886-06-2 C₂₀H₂₀ClN₅O*ClH 

Relevant articles and documents

Discovery of novel 2,4-disubstituted pyrimidines as Aurora kinase inhibitors

In order to explore novel Aurora kinase inhibitors, a series of novel 2,4-disubstituted pyrimidines were designed, synthesized and evaluated their in vitro anti-proliferative activities against a panel of cancerous cell lines (A549, HCT-116 and MCF-7). Among them, compound 12a showed the moderate to high anti-proliferative activities against A549 (IC50 = 12.05 ± 0.45 μM), HCT-116 (IC50 = 1.31 ± 0.41 μM) and MCF-7 (IC50 = 20.53 ± 6.13 μM) cells, as well as the Aurora A and Aurora B inhibitory activities with the IC50 values of 309 nM and 293 nM, respectively. Furthermore, compound 12a induced apoptosis by upregulated the pro-apoptotic proteins Bax and decreased the anti-apoptotic protein Bcl-xl in HCT-116 cells. Moreover, the molecular docking study showed that compound 12a had good binding modes with Aurora A and Aurora B and the bioinformatics prediction discovered that compound 12a exhibited good drug likeness using SwissADME. Taken together, these results indicated that 12a may be a potential anticancer compound that was worthy of further development as Aurora kinase inhibitor.

AURORA KINASE INHIBITORS AND METHODS OF MAKING AND USING THEREOF

Described herein are inhibitors of Aurora kinase and their use in the treatment of cancer. Methods of screening for selective inhibitors of Aurora kinases are also disclosed.

Cyclin-dependent kinase 4 inhibitors as a treatment for cancer. Part 2: Identification and optimisation of substituted 2,4-bis anilino pyrimidines

Through chemical modification and X-ray crystallography we identified the 2,4-bis anilino pyrimidines as potent inhibitors of CDK4. Herein, we describe the optimisation of this series.